TrialJournal for immunotherapy of cancer2022

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Elizabeth J Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.